Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4O15

The crystal structure of a mutant NAMPT (S165F) in complex with GNE-618

Summary for 4O15
Entry DOI10.2210/pdb4o15/pdb
Related4O13 4O14 4O16 4O17 4O18 4O19 4O1A 4O1B 4O1C 4O1D 4O28
DescriptorNicotinamide phosphoribosyltransferase, N-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}benzyl)-2H-pyrazolo[3,4-b]pyridine-5-carboxamide, PHOSPHATE ION, ... (5 entities in total)
Functional Keywordstransferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (human)
Cellular locationNucleus: P43490
Total number of polymer chains2
Total formula weight115491.90
Authors
Oh, A.,Coons, M.,Brillantes, B.,Wang, W. (deposition date: 2013-12-15, release date: 2014-10-22, Last modification date: 2024-02-28)
Primary citationWang, W.,Elkins, K.,Oh, A.,Ho, Y.C.,Wu, J.,Li, H.,Xiao, Y.,Kwong, M.,Coons, M.,Brillantes, B.,Cheng, E.,Crocker, L.,Dragovich, P.S.,Sampath, D.,Zheng, X.,Bair, K.W.,O'Brien, T.,Belmont, L.D.
Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors.
Plos One, 9:e109366-e109366, 2014
Cited by
PubMed Abstract: Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metabolism. However, the development of drug resistance commonly limits the efficacy of cancer therapeutics. This study identifies mutations in NAMPT that confer resistance to a novel NAMPT inhibitor, GNE-618, in cell culture and in vivo, thus demonstrating that the cytotoxicity of GNE-618 is on target. We determine the crystal structures of six NAMPT mutants in the apo form and in complex with various inhibitors and use cellular, biochemical and structural data to elucidate two resistance mechanisms. One is the surprising finding of allosteric modulation by mutation of residue Ser165, resulting in unwinding of an α-helix that binds the NAMPT substrate 5-phosphoribosyl-1-pyrophosphate (PRPP). The other mechanism is orthosteric blocking of inhibitor binding by mutations of Gly217. Furthermore, by evaluating a panel of diverse small molecule inhibitors, we unravel inhibitor structure activity relationships on the mutant enzymes. These results provide valuable insights into the design of next generation NAMPT inhibitors that offer improved therapeutic potential by evading certain mechanisms of resistance.
PubMed: 25285661
DOI: 10.1371/journal.pone.0109366
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.8 Å)
Structure validation

227344

건을2024-11-13부터공개중

PDB statisticsPDBj update infoContact PDBjnumon